MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure (Q79642618)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

title

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

1 reference

R Dreicer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

W M Stadler

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

F R Ahmann

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

T Whiteside

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

N Bizouarne

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

B Acres

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

J-M Limacher

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

P Squiban

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

A Pantuck

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

18 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

24 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

379-386

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18931824%20AND%20SRC:MED&resulttype=core&format=json

Gene expression profiling identifies clinically relevant subtypes of prostate cancer

24 December 2019

cites work

1 reference

12 December 2020

Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2

1 reference

12 December 2020

MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage

1 reference

12 December 2020

A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas

1 reference

12 December 2020

Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines

1 reference

12 December 2020

Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis

1 reference

12 December 2020

Phase II trial of GM-CSF in advanced prostate cancer.

1 reference

12 December 2020

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

12 December 2020

Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice

1 reference

12 December 2020

MUC1 and the immunobiology of cancer

1 reference

12 December 2020

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality

1 reference

12 December 2020

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

1 reference

12 December 2020

Induction of minor histocompatiblity antigen HA-1-specific cytotoxic T cells for the treatment of leukemia after allogeneic stem cell transplantation

1 reference

12 December 2020

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

12 December 2020

Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay

1 reference

12 December 2020

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

1 reference

12 December 2020

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

1 reference

12 December 2020

Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.

1 reference

12 December 2020

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine

1 reference

12 December 2020

Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor

1 reference

12 December 2020

Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.

1 reference

12 December 2020

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells

1 reference

12 December 2020

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

12 December 2020

Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer

1 reference

12 December 2020

A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma

1 reference

12 December 2020